Month: January 2022

A family history of prostate or breast cancer is an obvious reason to test for gene mutations that are markers for potentially aggressive PCa. In fact, prostate cancer genomic screening guidelines from the National Comprehensive Cancer Network (NCCN) recommend germline genetic testing with or without genetic counseling for prostate cancer patients who have... keep reading

We all know how consumer demand spawns knockoffs of high-end goods, and how inferior the resulting imitations are. For instance, there’s a huge quality gap between a flea market “Rolex” vs. the original Swiss superstar. But a Rolex watch is not accessible for everyone, so in the interest of maintaining one’s image, compromise comes easily. keep reading

Do you use a statin drug to control cholesterol? If so, you are among the millions of U.S. adults who take this type of drug. According to a 2017 study, “The number of adults in the general population who reported using any statin increased from 21.8 million (17.9%) in 2002-2003 to 39.2 million (27.8%) in keep reading

In March, 2021 COVID-19 was named as the third leading cause of the death in the U.S. behind heart disease and cancer. In 2020, it was estimated that there were 191,930 new cases of prostate cancer (PCa), with an expected 33,330 men dying from the disease. We know that of all cancers, lung cancer is keep reading

What does the chest have to do with the brain? Aside from the role played by the brain in regulating life-sustaining involuntary breathing and heart rate, it doesn’t look like there’s much of a connection. However, French physician Philippe Grenier, a “respected expert in chest imaging and respiratory disease,” is enthusiastic about integrating Artificial Intelligence keep reading

UPDATE: August 20, 2024 Originally published January 10, 2022 If an accurate noninvasive urine test for prostate cancer (PCa) is the Holy Grail of screening, it may be at hand. It was not that long ago that we posted about pee samples for PCa-sniffing dogs and biosensors, but now there’s an amazing breakthrough. In April keep reading

I just read a terrific blog by a Chicago author, Howard Wolinsky, who has been on Active Surveillance for Wilensky 10 years. He has Gleason 3+3 prostate cancer—and is doing just fine! As he reflects on his own experience, he quotes from several experts in urologic surgery and clinical pathology. Spoiler alert: he articulates both keep reading

“Lutetium-177 (¹⁷⁷Lu)-PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.” Since we posted the 2017 blog below, research into Lutetium-177 has been ongoing. The opening quote for this update comes from a September, 2021 published clinical study by Sartor et al... keep reading

I was fascinated by a revealing new research study concerning prostate cancer (PCa) and the gut microbiome. Even though the prostate gland and the intestines are both located in the abdominal cavity, nature has ensured that they are separated so dangerous E. coli bacteria in the bowel can’t contaminate the urinary/sexual system. However, there may keep reading

There is a difference between insignificant and significant prostate cancer (PCa). While opinion remains mixed regarding the need to treat insignificant PCa immediately—or whether some cases might never need treatment—agreement is virtually universal that significant PCa is not trustworthy and should thus be dealt with as soon as possible keep reading